Catalyst
Slingshot members are tracking this event:
Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
PBYI |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 21, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase Iii Trial, Pb272, Neratinib, Adjuvant Her2-positive Breast Cancer, Extenet Trial, Trastuzumab